Correction: Interleukin-6: a new therapeutic target by Smolen, Josef S & Maini, Ravinder N
Page 1 of 1
(page number not for citation purposes)
Available online http://arthritis-research.com/content/8/6/407
Following the publication of the above article [1], we noticed
that due to an administrative oversight the Competing
interests section was incomplete and should read as follows:
JSS has received financial compensation from and served on
advisory boards for Roche and is an investigator in clinical
trials of tocilizumab. RNM has received consulting fees from
Chugai; served on an ad hoc advisory board for Roche; and
was responsible for the planning and preparation for
publication of the Phase II European (CHARISMA) trial of
tocilizumab with and without methotrexate. A patent for co-
administration of methotrexate and tocilizumab for the
treatment of rheumatoid arthritis, of which RNM is named as a
co-inventor, has been applied for and fully assigned to Chugai.
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